Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
6 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Neumora Therapeutics, Inc.
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
August 14, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
June 20, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
May 14, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 06, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
April 15, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
March 13, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
January 22, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
December 12, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
November 27, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 01, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics to Participate in Upcoming Conferences in November
October 30, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
October 10, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Tickers
NMRA
Neumora Therapeutics Announces Pricing of Initial Public Offering
September 14, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
July 18, 2023
From
Neumora Therapeutics, Inc.
Via
Business Wire
Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer
July 18, 2023
From
Neumora Therapeutics, Inc.
Via
Business Wire
Neumora Therapeutics Announces $112 Million Series B Financing
October 11, 2022
From
Neumora Therapeutics, Inc.
Via
Business Wire
Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University
February 17, 2022
From
Neumora Therapeutics, Inc.
Via
Business Wire
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
October 07, 2021
From
Neumora Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.